Chi Hong-jie, Gao Song, Yang Xin-chun, Cai Jun, Zhao Wen-shu, Sun Hao, Geng Yong-Jian
Department of Cardiology, Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Cardiology. 2015;131(4):236-44. doi: 10.1159/000381280. Epub 2015 May 12.
Induced pluripotent stem cells (iPSCs) are generated by reprogramming human somatic cells through the overexpression of four transcription factors: Oct4, Sox2, Klf4 and c-Myc. iPSCs are capable of indefinite self-renewal, and they can differentiate into almost any type of cell in the body. These cells therefore offer a highly valuable therapeutic strategy for tissue repair and regeneration. Recent experimental and preclinical research has revealed their potential for cardiovascular disease diagnosis, drug screening and cellular replacement therapy. Nevertheless, significant challenges remain in terms of the development and clinical application of human iPSCs. Here, we review current progress in research related to patient-specific iPSCs for ex vivo modeling of cardiovascular disorders and drug screening, and explore the potential of human iPSCs for use in the field of cardiovascular regenerative medicine.
诱导多能干细胞(iPSC)是通过过表达四种转录因子Oct4、Sox2、Klf4和c-Myc对人类体细胞进行重编程而产生的。iPSC能够无限自我更新,并且可以分化为体内几乎任何类型的细胞。因此,这些细胞为组织修复和再生提供了一种极具价值的治疗策略。最近的实验和临床前研究揭示了它们在心血管疾病诊断、药物筛选和细胞替代治疗方面的潜力。然而,在人类iPSC的开发和临床应用方面仍然存在重大挑战。在此,我们综述了与用于心血管疾病体外建模和药物筛选的患者特异性iPSC相关的研究当前进展,并探讨了人类iPSC在心血管再生医学领域的应用潜力。